Movember: an everlasting impact on the face of men’s health

By Dr Mark Steedman, PhD, Manager, Centre for Health Solutions

Movember

The moustache has a fascinating history – popular at times, eschewed at others, but always competing in the popularity stakes against the beard. From a fashion symbol popularised by monarchs of the past, to practical restrictions on beards but not moustaches because of press articles linking germs with beards and rules preventing bearded men from handling food. As a result, the popularity of the beard versus the moustache has ebbed and flowed.1 I’ve seen this even in my own lifetime. While there were a few famous moustaches that adorned the faces of Hollywood stars and musicians, for the most part, the 1990s saw the moustache fall seriously out of fashion.

Continue reading

Posted on 15/11/2019 | 0 Comments

Intelligent drug discovery: Powered by AI

By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-intelligent-drug-discovery

Next week at the 2019 Global Financial Times Pharmaceutical and Biotechnology conference in London, we will formally launch the second in our series of reports on how artificial intelligence (AI) is driving the digital transformation of biopharma. This second report, Intelligent drug discovery: Powered by AI, explores the rise of ‘disruptive AI for drug discovery’ companies and the challenges and opportunities for biopharma in using AI technologies to help find new, more precise, targeted treatments.1 This blog highlights the key takeaways from our report.

Continue reading

Posted on 08/11/2019 | 0 Comments

Shaping the future of UK healthcare: Closing the digital gap

By Karen Taylor, Director, Centre for Health Solutions

Brain

Last month I participated in a panel discussion at the Technology Services Association International Technology-Enabled Care Conference on the subject of Citizen Powered Technological Enablement.1 In anticipation of the panel discussion, I agreed to write a blog on our July 2019 research report Closing the digital gap: Shaping the future of UK healthcare.2 This week, I thought I’d repurpose this blog as a Centre blog, to highlight some the challenges currently being faced in delivering a digital first NHS. Next month we will return to this issue with a focus on primary care.

Continue reading

Posted on 01/11/2019 | 0 Comments

‘Coop-etition’ could grow as medtech companies prepare for transformational innovation

By Glenn Snyder, Principal, MedTech Practice Leader, Deloitte Consulting LLP

Coop

This week’s blog, by Glenn Snyder from the US firm, first appeared on the US Center for Health Solutions blog site. It was published in advance of the AdvaMed annual conference in Boston, where he led a session on transformational innovation with a panel of CEOs from three medical technology companies. During the session, they examined how innovation is changing thanks to the value-based marketplace and the evolution of digitally-enabled devices. They also discussed how start-ups and companies from outside of the medtech space are driving rapid changes in the market in ways that leverage their strength rather than traditional medtech strengths.

Continue reading

Posted on 25/10/2019 | 0 Comments

Will you take on Cancer Research UK’s Veg Pledge challenge this November?

By Krissie Ferris, Research Analyst, Centre for Health Solutions

Deloitte-uk-cancer-research

Cancer Research UK (CRUK) is encouraging the nation to take the ‘Veg Pledge’ this November and go vegetarian or vegan for one month.1 Those taking part can obtain plenty of tips, recipes and fundraising ideas from CRUK to help them through their challenge. Being vegan myself, and having just completed my first week at Deloitte, it was great to see so many plant-based offerings on the menu at our snazzy 1 New Street Square canteen. Providing more plant-based options is the main way employers are responding to the cultural shift that is turning more and more people towards plant-based diets (see Deloitte’s 2019 article ‘Plant-based alternatives, Driving industry M&A’).2 However, there are many other approaches that leading companies like Deloitte can take to encourage and inspire plant-based eating in the workplace. This blog explores those opportunities and the benefits of plant-based eating.

Continue reading

Posted on 18/10/2019 | 0 Comments

Steering the ship – Governance for a new world

By Mark Green, Director Board Advisory

Healthcare

The NHS Long Term Plan (LTP) and the development of STPs, ICSs, ICPs and now PCNs (see Figure 1), not only makes for a mouthful of acronyms, but also raises the prospect of a governance headache. While the LTP requires every NHS organisation and their local partners to become part of a geographically-based ICS by April 2021, and recognises that it’s possible to implement the necessary changes without primary legislation, it also acknowledges that legislative change could make implementation easier and faster.1 However, there are currently limited signs of any primary legislation being introduced in the short to medium term to support and guide the shift in health and care policy.

Continue reading

Posted on 11/10/2019 | 0 Comments

Intelligent biopharma: Forging the links across the value chain

By Mark Steedman, PhD, Manager, Centre for Health Solutions

Deloitte-uk-intelligent-biopharma

This week, we have launched the first in a series of reports on artificial intelligence (AI) and its potential impact in driving the digital transformation of biopharma. This overview report, Intelligent biopharma: Forging the links across the value chain, explores the challenges and opportunities in AI adoption and the potential ways that AI might impact the different segments of the biopharma value chain (see Figure 1).1

Continue reading

Posted on 04/10/2019 | 0 Comments

Can objective knowledge on GM foods change public opinion?

By Elliot Birtwhistle, Deloitte Consulting

Salads

Genetic modification (GM) is the process of altering the genes of a living organism. The words invoke images of secret government labs and scientists in white hazmat suits that inject rodents with glowing liquid. The reality is somewhat more nuanced. Genetic modification either inserts a gene, or a small number of genes into a plant or animal – or ‘silences’ an existing gene(s) to produce a genetically modified organism. The applications are widespread and include medicines, consumer products and commercial agriculture. This week’s blog explores some of the issues surrounding GM foods.

Continue reading

Posted on 27/09/2019 | 0 Comments

So, just how attractive are Biosimilars for pharma companies?

By Peter Wallace, Partner in Consulting

Deloitte-uk-biosimilars-for-pharma-companies

Last week’s blog discussed the cost effectiveness of biosimilars and the extent to which they offer value for money for healthcare systems.1 This week’s blog, by Peter Wallace, our lead Partner for digital transformation of Life Sciences and Healthcare, looks at the issue through the lens of the pharma company.

Continue reading

Posted on 20/09/2019 | 0 Comments

The cost-effectiveness of biosimilars: Delivering value for money from pharma spending

By Karen Taylor and Pratik Avhad, Centre for Health Solutions

Deloitte-uk-cost-effectiveness-of-biosimilars

Two months ago, I participated in a Westminster Health Forum panel discussing Biologics and Biosimilars. My remit was to discuss the cost effectiveness of biosimilars and their contribution to value for money in pharma spending. This week’s blog shares the findings from the research we did for the presentation.

Continue reading

Posted on 13/09/2019 | 0 Comments

Delivering the efficiency challenge: The case for system wide efficiency programmes

By Dr Christine Armistead and Gurminder Khaira

Lshc

The combination of significant financial challenges, growing demand for services and major workforce shortages demands a different approach if the NHS is deliver the ambitions set out in the Long Term Plan (LTP). A key priority is the need to put the NHS back onto a sustainable financial footing. This includes major reforms to the NHS’ financial architecture, payment systems and incentives, and a requirement for the NHS to deliver cash-releasing productivity growth of at least 1.1 per cent a year.1

Continue reading

Posted on 06/09/2019 | 0 Comments